University of Pennsylvania researchers have found that implantable cardioverter-defibrillators play a role in patients being able to lead longer and more active lives. The study is the first to analyze quality of life and cost in "primary prevention" ICD patients, that is patients with no prior history of abnormal heart rhythms, but whose heart disease may increase their risk of sudden cardiac death. It is also among the first to verify the effectiveness of ICDs in patients who were not enrolled in clinical trials. The study was funded by InHealth, whose mission is to research (and, if results are favorable, promote) the benefits of innovative medical technologies. It is studies like these that the device industry needs to enhance its standing among the mainstream public and media.